Summary of Study ST001815
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001148. The data can be accessed directly via it's Project DOI: 10.21228/M89Q5T This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
Study ID | ST001815 |
Study Title | Metabolic Markers of Methotrexate Response in Juvenile Idiopathic Arthritis |
Study Type | Clinical |
Study Summary | Plasma from children with juvenile idiopathic arthritis collected pre-treatment and following 3 months of treatment with methotrexate were submitted for metabolomic profiling to the NIH West Coast Metabolomics Center. |
Institute | University of Kansas |
Department | Pharmacy Practice |
Laboratory | Funk Lab |
Last Name | funk |
First Name | ryan |
Address | 2106 Olathe Boulevard |
ryanfunk@kumc.edu | |
Phone | 9135885000 |
Submit Date | 2021-05-18 |
Num Groups | 1 |
Total Subjects | 30 |
Num Males | 9 |
Num Females | 21 |
Analysis Type Detail | GC-MS/LC-MS |
Release Date | 2021-06-17 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR001148 |
Project DOI: | doi: 10.21228/M89Q5T |
Project Title: | Metabolic Markers of Methotrexate Response in Juvenile Idiopathic Arthritis |
Project Type: | Clinical |
Project Summary: | Association of changes in the plasma metabolome with clinical response to methotrexate in children with juvenile idiopathic arthritis. |
Institute: | University of Kansas |
Department: | Pharmacy Practice |
Laboratory: | Funk |
Last Name: | Funk |
First Name: | Ryan |
Address: | 2106 Olathe Boulevard, Kansas City, Kansas, 66160, USA |
Email: | ryanfunk@kumc.edu |
Phone: | 9139456904 |
Funding Source: | KL2TR002367 |
Subject:
Subject ID: | SU001892 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Age Or Age Range: | 1.8 to 17 years |
Gender: | Not applicable |
Factors:
Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)
mb_sample_id | local_sample_id | Subject | Timepoint |
---|---|---|---|
SA168914 | 10.0 | 10 | - |
SA168915 | 10.3 | 10 | 3 |
SA168916 | 11.0 | 11 | - |
SA168917 | 11.3 | 11 | 3 |
SA168918 | 12.0 | 12 | - |
SA168919 | 12.3 | 12 | 3 |
SA168920 | 14.0 | 14 | - |
SA168921 | 14.3 | 14 | 3 |
SA168922 | 20.0 | 20 | - |
SA168923 | 20.3 | 20 | 3 |
SA168924 | 22.0 | 22 | - |
SA168925 | 22.3 | 22 | 3 |
SA168926 | 24.0 | 24 | - |
SA168927 | 24.3 | 24 | 3 |
SA168928 | 25.0 | 25 | - |
SA168929 | 25.3 | 25 | 3 |
SA168930 | 29.0 | 29 | - |
SA168931 | 29.3 | 29 | 3 |
SA168932 | 2.0 | 2 | - |
SA168933 | 2.3 | 2 | 3 |
SA168934 | 30.0 | 30 | - |
SA168935 | 30.3 | 30 | 3 |
SA168936 | 35.0 | 35 | - |
SA168937 | 35.3 | 35 | 3 |
SA168938 | 36.0 | 36 | - |
SA168939 | 36.3 | 36 | 3 |
SA168940 | 37.0 | 37 | - |
SA168941 | 37.3 | 37 | 3 |
SA168942 | 38.0 | 38 | - |
SA168943 | 38.3 | 38 | 3 |
SA168944 | 40.0 | 40 | - |
SA168945 | 40.3 | 40 | 3 |
SA168946 | 45.0 | 45 | - |
SA168947 | 45.3 | 45 | 3 |
SA168948 | 49.0 | 49 | - |
SA168949 | 49.3 | 49 | 3 |
SA168950 | 50.0 | 50 | - |
SA168951 | 50.3 | 50 | 3 |
SA168952 | 51.0 | 51 | - |
SA168953 | 51.3 | 51 | 3 |
SA168954 | 58.0 | 58 | - |
SA168955 | 58.3 | 58 | 3 |
SA168956 | 59.0 | 59 | - |
SA168957 | 59.3 | 59 | 3 |
SA168958 | 60.0 | 60 | - |
SA168959 | 60.3 | 60 | 3 |
SA168960 | 61.0 | 61 | - |
SA168961 | 61.3 | 61 | 3 |
SA168962 | 62.0 | 62 | - |
SA168963 | 62.3 | 62 | 3 |
SA168964 | 63.0 | 63 | - |
SA168965 | 64.0 | 64 | - |
SA168966 | 63.6 | 64 | 3 |
SA168967 | 64.3 | 64 | 3 |
SA168968 | 66.0 | 66 | - |
SA168969 | 66.3 | 66 | 3 |
SA168970 | 8.0 | 8 | - |
SA168971 | 8.3 | 8 | 3 |
SA168972 | 9.0 | 9 | - |
SA168973 | 9.3 | 9 | 3 |
Showing results 1 to 60 of 60 |
Collection:
Collection ID: | CO001885 |
Collection Summary: | Venous blood samples were collected in K2-EDTA containing tubes prior to initiation of MTX and at the patient’s routine 3 month follow up clinic visit along with routine laboratory blood draws. Venous blood samples (10 mL) collected at each timepoint were separated into plasma and cellular fractions by centrifugations at 2,000 RPM in a Beckman tabletop centrifuge for 10 minutes. The resulting supernatant (i.e. plasma fraction) was separated into aliquots and stored at -80 ºC prior to analysis. |
Sample Type: | Blood (plasma) |
Storage Conditions: | -80℃ |
Additives: | K2EDTA |
Treatment:
Treatment ID: | TR001905 |
Treatment Summary: | Plasma samples were acquired from a single-center prospective cohort of JIA patients. The study included patients diagnosed with JIA requiring initiation of MTX for inadequately controlled disease without the need for biological therapy at initiation. Diagnosis of JIA was established based on the Edmonton 2001 International League of Associations of Rheumatology (ILAR) criteria for JIA. Patients were initiated on a standardized MTX dose of 15 mg/m2 weekly by subcutaneous or oral administration along with 1 mg folic acid daily. Concurrent medications allowed included nonsteroidal anti-inflammatory drugs (NSAIDs) and daily low-dose steroids (the lesser of 0.2 mg/kg/day or 10 mg). Intra-articular steroid injections (IASI) were allowed, however injected joints were counted as “active” at follow up to reduce the potential bias resulting from IASI. |
Treatment Compound: | Methotrexate |
Treatment Route: | Oral or Subcutaneous |
Treatment Dose: | 15 mg/m^2 |
Treatment Doseduration: | 3 months |
Sample Preparation:
Sampleprep ID: | SP001898 |
Sampleprep Summary: | Plasma samples were sent to the West Coast Metabolomics Center and were processed on laboratory Standard Operating Procedures for Sample Preparation of Blood Plasma or Serum Samples for Lipidomic, Biogenic Amine, and Primary Metabolomic Analysis using a biphasic MeOH/MTBE/Water extraction procedure. The upper organic phase was used for lipidomics analysis and the aqueous phase was used for analysis of primary metabolism and biogenic amines. |
Combined analysis:
Analysis ID | AN002944 | AN002945 | AN002946 | AN002947 |
---|---|---|---|---|
Analysis type | MS | MS | MS | MS |
Chromatography type | GC | HILIC | Reversed phase | Reversed phase |
Chromatography system | Leco Pegasus IV GC | Agilent 6530 | Agilent 6530 | Agilent 6530 |
Column | Restek Rtx-5Sil (30m x 0.25mm,0.25um) | Waters Acquity BEH Amide (150 x 2.1mm,1.7um) | Waters Acquity CSH C18 (100 x 2.1mm,1.7um) | Waters Acquity CSH C18 (100 x 2.1mm,1.7um) |
MS Type | EI | ESI | ESI | ESI |
MS instrument type | GC-TOF | QTOF | QTOF | QTOF |
MS instrument name | Leco Pegasus IV TOF | Agilent 6530 QTOF | Agilent 6530 QTOF | Agilent 6550 QTOF |
Ion Mode | NEGATIVE | POSITIVE | POSITIVE | NEGATIVE |
Units | Peak Height Intensity | Peak Height Intensity | Peak Height Intensity | Peak Height Intensity |
Chromatography:
Chromatography ID: | CH002180 |
Chromatography Summary: | Primary Metabolism |
Instrument Name: | Leco Pegasus IV GC |
Column Name: | Restek Rtx-5Sil (30m x 0.25mm,0.25um) |
Chromatography Type: | GC |
Chromatography ID: | CH002181 |
Chromatography Summary: | Biogenic Amines |
Instrument Name: | Agilent 6530 |
Column Name: | Waters Acquity BEH Amide (150 x 2.1mm,1.7um) |
Chromatography Type: | HILIC |
Chromatography ID: | CH002182 |
Chromatography Summary: | Lipidomics |
Instrument Name: | Agilent 6530 |
Column Name: | Waters Acquity CSH C18 (100 x 2.1mm,1.7um) |
Column Temperature: | 65 |
Flow Rate: | 0.6 mL/min |
Solvent A: | 60% acetonitrile/40% water; 0.1% formic acid; 10 mM ammonium formate |
Solvent B: | 90% isopropanol/10% acetonitrile; 0.1% formic acid; 10 mM ammonium formate |
Chromatography Type: | Reversed phase |
MS:
MS ID: | MS002734 |
Analysis ID: | AN002944 |
Instrument Name: | Leco Pegasus IV TOF |
Instrument Type: | GC-TOF |
MS Type: | EI |
MS Comments: | MS acquisition, data processing, and feature assignments were conducted at the West Coast Metabolomics Center. Please reference the attached protocols. |
Ion Mode: | NEGATIVE |
Analysis Protocol File: | Data_Dictionary_Fiehn_laboratory_GCTOF_MS_primary_metabolism_10-15-2013_general.pdf |
MS ID: | MS002735 |
Analysis ID: | AN002945 |
Instrument Name: | Agilent 6530 QTOF |
Instrument Type: | QTOF |
MS Type: | ESI |
MS Comments: | MS acquisition, data processing, and feature assignments were conducted at the West Coast Metabolomics Center. Please reference the attached protocols. |
Ion Mode: | POSITIVE |
Analysis Protocol File: | Data_Dictionary_Fiehn_laboratory_HILIC_QTOF_MS.pdf |
MS ID: | MS002736 |
Analysis ID: | AN002946 |
Instrument Name: | Agilent 6530 QTOF |
Instrument Type: | QTOF |
MS Type: | ESI |
MS Comments: | MS acquisition, data processing, and feature assignments were conducted at the West Coast Metabolomics Center. Please reference the attached protocols. |
Ion Mode: | POSITIVE |
Analysis Protocol File: | Data_Dictionary_Fiehn_laboratory_CSH_QTOF_lipidomics.pdf |
MS ID: | MS002737 |
Analysis ID: | AN002947 |
Instrument Name: | Agilent 6550 QTOF |
Instrument Type: | QTOF |
MS Type: | ESI |
MS Comments: | MS acquisition, data processing, and feature assignments were conducted at the West Coast Metabolomics Center. Please reference the attached protocols. |
Ion Mode: | NEGATIVE |
Analysis Protocol File: | Data_Dictionary_Fiehn_laboratory_CSH_QTOF_lipidomics.pdf |